| Ytd | 71.87% | |
| 1y | -42.94% |
| Open | 22.50 | Prev Close | 22.65 | Low | 22.30 | High | 22.76 | Mkt Cap | 1.33B |
| Vol | 847.99K | Avg Vol | 1.15M | EPS | 180.58 | P/E | 0.12 | Forward P/E | -5.90 |
| Beta | 1.72 | Short Ratio | 8.91 | Inst. Own | 85.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 20.28 | 200-d Avg | 15.29 | 1yr Est | 39.00 |
VOR News
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the pr
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst c
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst c
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis p
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitac
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for
The conditional approval is supported by positive efficacy and safety data from RemeGen's comple
First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in Chi
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on p
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnolo
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the pr
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks w
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.73) per share which beat the analyst con
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis p
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empiric
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa
The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor
Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) was the target of a large growth in short interes
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 484,104
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) Director Ra Capital Management, L.P. sold 135,201
Vor Biopharma Inc. has pivoted to immunology, raising over $500m in 2025 to advance telitacicept for
U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend.
XCUR: 176% | Exicure shares are trading higher after the company announced results from its complete
